Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Clinical trial NCT02839707 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02839707
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Fallopian Tube High Grade Serous Adenocarcinoma Ovarian High Grade Serous Adenocarcinoma Ovarian Seromucinous Carcinoma Primary Peritoneal High Grade Serous Adenocarcinoma Recurrent Fallopian Tube Carcinoma Recurrent Fallopian Tube Clear Cell Adenocarcinoma Recurrent Fallopian Tube Endometrioid Adenocarcinoma Recurrent Fallopian Tube Undifferentiated Carcinoma Recurrent Ovarian Carcinoma Recurrent Ovarian Clear Cell Adenocarcinoma Recurrent Ovarian Endometrioid Adenocarcinoma Recurrent Ovarian Undifferentiated Carcinoma

Start date: 2017-06-23
Primary completion: 2023-05-09
Enrollment: 444

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.